Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities
NASHUA, N.H., Jan. 24, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company’s breast artificial intelligence (AI) platform was granted an Authorization to Operate (ATO) from the U.S. Department of Defense (DoD). iCAD’s breast AI platform includes ProFound AI®, which became the first AI software for digital breast tomosynthesis (DBT) to be FDA cleared in 2018.
“It is a significant accomplishment for our technology to achieve this authorization,” said